ABSTRACT
The purpose of this guideline, which is prepared by the neuropsychiatry imaging task group of the Turkey Association of Nuclear Medicine, is to help nuclear medicine physicians in their practice of dopaminergic imaging in Parkinsonian syndromes. Nuclear medicine imaging methods can evaluate both presynaptic and postsynaptic functions of the dopaminergic system in the brain. Single photon emission computed tomography (SPECT) radiopharmaceuticals for dopamine transporters (DAT) are frequently used in presynaptic dopaminergic imaging. Apart from this, it is possible to image other presynaptic molecular targets that are involved in dopamine synthesis and postsynaptic dopamine-2 receptors with various SPECT and positron emission tomography radiopharmaceuticals. However, in our country, only a single SPECT radiopharmaceutical that targets DAT is approved for routine clinical use. Therefore, this guideline aims to cover the procedure related to DAT SPECT examination.
Keywords:
Parkinsonian syndromes, dopamine transporters, single photon emission computed tomography
References
1
Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain 2017;140:266-278.
2
Brooks DJ. Molecular imaging of dopamine transporters. Ageing Res Rev 2016;30:114-121.
3
Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123) I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37:443-450.
4
Palermo G, Ceravolo R. Molecular Imaging of the Dopamine Transporter. Cells 2019;8:872.
5
Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. Clin Nucl Med 2017;42:847-852.
6
Djang DS, Janssen MJ, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012;53:154-163.
7
Van Laere K, Varrone A, Booij J, et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37:434-442.
8
Sonni I, Fazio P, Schain M, et al. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. J Nucl Med 2016;57:1529-1534.
9
Fallahi B, Esmaeili A, Beiki D, et al. Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson’s disease versus other progressive movement disorders. Ann Nucl Med 2016;30:153-162.
10
Hellwig S, Amtage F, Kreft A, et al. [18F] FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012;79:1314-1322.
11
Treglia G, Cason E, Stefanelli A, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 2012;22:43-55.
12
Dickson JC, Tossici-Bolt L, Sera T, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging 2012;39:188-197.
13
Dickson JC, Tossici-Bolt L, Sera T, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging 2010;37:23-35.
14
Tossici-Bolt L, Dickson JC, Sera T, et al. [123I] FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys 2017;4:8.
15
Tossici-Bolt L, Dickson JC, Sera T, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging 2011;38:1529-1540.
16
Varrone A, Dickson JC, Tossici-Bolt L, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 2013;40:213-227.
17
Nicastro N, Garibotto V, Burkhard PR. 123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy. Clin Nucl Med 2018;43:33-36.
18
Brigo F, Matinella A, Erro R, Tinazzi M. [123I] FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 2014;21:1369-1390.
19
Bauckneht M, Chincarini A, De Carli F, et al. Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: A systematic review and meta-analysis. Sleep Med Rev 2018;41:266-274.
20
Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Movement Disord 2015;30:1600-1611.
21
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.
22
Filippi M, Agosta F, Barkhof F, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012;19:131-140.
23
Proebstl L, Kamp F, Manz K, et al. Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. Eur Psychiatry 2019;59:15-24.
24
Kamp F, Proebstl L, Penzel N, et al. Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. Neuropsychopharmacology 2019;44:660-667.
25
Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424-438.
26
Booij J, de Jong J, de Bruin K, Knol R, de Win MML, Eck-Smit BLF. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007;48:359-366.
27
Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced Parkinsonism. Mov Disord 2014;29:575-577.
28
Mattsson S, Johansson L, Svegborn SL, et al. Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44(2 Suppl):7-321.
29
Grosset DG, Tatsch K, Oertel WH, et al. Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane I-123 Injection (DaTscan). Journal of Nuclear Medicine 2014;55:1281-1287.
30
Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: Present and future. Metabolism 2015;64:40-46.
31
Fazio P, Svenningsson P, Cselenyi Z, Halldin C, Farde L, Varrone A. Nigrostriatal dopamine transporter availability in early Parkinson’s disease. Mov Disord 2018;33:592-599.
32
Marshall VL, Reininger CB, Marquardt M, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500-508.
33
Booij J, Dubroff J, Pryma D, et al. Diagnostic Performance of the Visual Reading of (123) I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia. J Nucl Med 2017;58:1821-1826.
34
Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013;136:2419-2431.
35
Marek K, Seibyl J, Eberly S, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014;82:1791-1797.
36
Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson’s disease. J Neurol Neurosurg Psychiatry 2013;84:122-129.
37
Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular Parkinsonism: deconstructing a syndrome. Mov Disord 2015;30:886-894.
38
Thomas AJ, Attems J, Colloby SJ, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 2017;88:276-283.
39
van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)] FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2016;43:1060-1066.
40
Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 1998;39:1500-1508.
41
Kuo PH, Lei HH, Avery R, et al. Evaluation of an Objective Striatal Analysis Program for Determining Laterality in Uptake of 123I-Ioflupane SPECT Images: Comparison to Clinical Symptoms and to Visual Reads. J Nucl Med Technol 2014;42:105-108.
42
Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 2006;33:1491-1499.
43
Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
44
Hsu CC, Chang YH, Lin WC, et al. The feasibility of using CT-guided ROI for semiquantifying striatal dopamine transporter availability in a hybrid SPECT/CT system. Scientific World Journal 2014;2014:879497.
45
Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging 2007;34:1240-1253.
46
Matesan M, Gaddikeri S, Longfellow K, et al. I-123 DaTscan SPECT Brain Imaging in Parkinsonian Syndromes: Utility of the Putamen-to-Caudate Ratio. J Neuroimaging 2018;28:629-634.
47
Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson’s disease patients. J Nucl Med 2007;48:857-864.
48
Nobili F, Naseri M, De Carli F, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 2013;40:565-573.
49
Simuni T, Siderowf A, Lasch S, et al. Longitudinal Change of Clinical and Biological Measures in Early Parkinson’s Disease: Parkinson’s Progression Markers Initiative Cohort. Mov Disord 2018;33:771-782.
